ENJAYMO 50 mg/ml, solution for infusion bottle, 22 ml
Active ingredients: Sutimlimab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for infusionbottle, 22 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ENJAYMO 50 mg/ml, solution pour perfusion
- Pharmaceutical form
- solution pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 22 ml
- Marketing authorisation holder
- RECORDATI RARE DISEASES
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 18 Mar 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
69505243CIP73026656CIP133400930266564Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SUTIMLIMABsolution | 50 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.